Nodular lesions of monocvtic component in myelodysplastic syndrome

American Journal of Clinical Pathology

Volumn 110, Issue 2, 1998, Pages 154-162

  Mongkonsritragoon, Wichean ^a   Letendre, Louis ^a   Qian, Junqi ^a   Li, Chin Yang ^a  

^a MAYO CLINIC   (United States)

Author keywords

Drug resistance; Monocytic nodules; Myelodysplastic syndrome

Indexed keywords

BLEOMYCIN; CD68 ANTIGEN; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ETOPOSIDE; GLUTATHIONE TRANSFERASE; IDARUBICIN; KI 67 ANTIGEN; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; PREDNISONE; PROTEIN P53; RETINOBLASTOMA PROTEIN; TIOGUANINE; VINCRISTINE; VINCRISTINE SULFATE; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; GLUTATHIONE TRANSFERASE P1; GSTP1 PROTEIN, HUMAN; ISOENZYME; TUMOR ANTIGEN;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; BONE MARROW EXAMINATION; CASE REPORT; CHROMOSOME 11; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL FEATURE; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LABORATORY TEST; MALE; MONOCYTE; MYELODYSPLASTIC SYNDROME; PARTIAL TRISOMY 9; PHYSICAL EXAMINATION; PRIORITY JOURNAL; REFRACTORY ANEMIA; BONE MARROW; CENTROMERE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY;

ADULT; AGED; ANTIGENS, NEOPLASM; BONE MARROW; CENTROMERE; DNA TOPOISOMERASES, TYPE II; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; FEMALE; GLUTATHIONE S-TRANSFERASE PI; GLUTATHIONE TRANSFERASE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; ISOENZYMES; KI-67 ANTIGEN; MALE; MIDDLE AGED; MONOCYTES; MYELODYSPLASTIC SYNDROMES; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031596027     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/110.2.154     Document Type: Article

References (54)

1. Tricot G, De Wolf-Peeters C, Hendrickx B, et al. Bone marrow histology in myelodysplastic syndromes, I: histological findings in myelodysplastic syndromes and comparison with bone marrow smears. Br J Haematol. 1984;57:423-430.
2. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature. 1991;351:453-456.
3. Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature. 1989;342:705-708.
4. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science. 1991;253:49-53.
5. Lane DP. Mutation of the p53 gene and accumulation of the p53 protein: common steps found in the majority of human cancers. In: Fortner JG, Rhoads JE, eds. Accomplishments in Cancer Research, 1990 Prize Year. Philadelphia, Pa: Lippincott; 1991:252.
6. Adamson DJ, Dawson AA, Bennett B, et al. p53 mutation in the myelodysplastic syndromes. Br J Haematol. 1995;89: 61-66.
7. Kitagawa M, Yoshida S, Kuwata T, et al. p53 expression in myeloid cells of myelodysplastic syndromes: association with evolution of overt leukemia. Am J Pathol. 1994;145:338-344.
8. Cheng J, Scully P, Shew JY, et al. Homozygous deletion of the retinoblastoma gene in an acute lymphoblastic leukemia (T) cell line. Blood. 1990;75:730-735.
9. Bookstein R, Shew JY, Chen PL, et al. Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science. 1990;247:712-715.
10. Hensel CH, Hsieh CL, Gazdar AF, et al. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 1990;50:3067-3072.
11. Ewen ME. The cell cycle and the retinoblastoma protein family. Cancer Metastasis Rev. 1994;13:45-66.
12. Helin K, Harlow E, Fattaey A. Inhibition of E2F-1 transactivation by direct binding of the retinoblastoma protein. Mol Cell Biol. 1993;13:6501-6508.
13. Cress WD, Johnson DG, Nevins JR. A genetic analysis of the E2F1 gene distinguishes regulation by Rb, p107, and adenovirus E4. Mol Cell Biol. 1993;13:6314-6325.
14. Flemington EK, Speck SH, Kaelin WG Jr. E2F-1-mediated transactivation is inhibited by complex formation with the retinoblastoma susceptibility gene product. Proc Natl Acad Sci U S A. 1993;90:6914-6918.
15. Hagemeier C, Cook A, Kouzarides T. The retinoblastoma protein binds E2F residues required for activation in vivo and TBP binding in vitro. Nucleic Acids Res. 1993;21:4998-5004.
16. Bandara LR, Buck VM, Zamanian M, et al. Functional synergy between DP-1 and E2F-1 in the cell cycle-regulating transcription factor DRTF1/E2F. EMBO J. 1993;12:4317-4324.
17. Helin K, Wu CL, Fataey AR, et al. Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation. Genes Dev. 1993;7:1850-1861.
18. Krek W, Livingston DM, Shirodkar S. Binding to DNA and the retinoblastoma gene product promoted by complex formation of different E2F family members. Science. 1993;262:1557-1560.
19. Hashimoto T, Takahashi R, Yandell DW, et al. Characterization of intragenic deletions in two sporadic germinal mutation cases of retinoblastoma resulting in abnormal gene expression. Oncogene. 1991;6:463-469.
20. Fung YK, Murphree AL, T'Ang A, et al. Structural evidence for the authenticity of the human retinoblastoma gene. Science. 1987;236:1657-1661.
21. Friend SH, Bernards R, Rogelj S, et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature. 1986;323:643-646.
22. Harbour JW, Lai SL, Whang-Peng J, et al. Abnormalities in structure and expression of the human retinoblastoma gene in SCLC. Science. 1988;241:353-357.
23. Lee EY, To H, Shew JY, et al. Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science. 1988;241:218-221.
24. Bookstein R, Rio P, Madreperla SA, et al. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc Natl Acad Sci U S A. 1990;87:7762-7766.
25. Batist G, Tulpule A, Sinha BK, et al. Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem. 1986;261:15544-15549.
26. Moscow JA, Cowan KH. Mukidrug resistance. J Natl Cancer Inst. 1988;80:14-20.
27. Chasseaud LF. The role of glutathione and glutathione S-transferases in the metabolism of chemical carcinogens and other electrophilic agents. Adv Cancer Res. 1979;29:175-274.
28. Jakoby WB. The glutathione S-transferases: a group of multifunctional detoxification proteins. Adv Enzymol Relat Areas Mol Biol. 1978;46:383-414.
29. Johnston JB, Israels LG, Goldenberg GJ, et al. Glutathione S-transferase activity, sulfhydryl group and glutathione levels, and DNA cross-linking activity with chlorambucil in chronic lymphocytic leukemia. J Natl Cancer Inst. 1990;82:776-779.
30. Gupta V, Singh SV, Ahmad H, et al. Glutathione and glutathione S-transferases in a human plasma cell line resistant to melphalan. Biochem Pharmacol. 1989;38:1993-2000.
31. D'Arpa P, Machlin PS, Ratrie H III, et al. cDNA cloning of human DNA topoisomerase I: catalytic activity of a 67.7-kDa carboxyl-terminal fragment. Proc Natl Acad Sci U S A. 1988;85:2543-2547.
32. Tsai-Pflugfelder M, Liu LF, Liu AA, et al. Cloning and sequencing of cDNA encoding human DNA topoisomerase II and localization of the gene to chromosome region 17q21-22. Proc Natl Acad Sci U S A. 1988;85:7177-7181.
33. Heck MM, Hittelman WN, Earnshaw WC. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci U S A. 1988;85:1086-1090.
34. Woessner RD, Chung TD, Hofmann GA, et al. Differences between normal and ros-transformed NIH-3T3 cells in expression of the 170kD and 180kD forms of topoisomerase II. Cancer Res. 1990;50:2901-2908.
35. Deffie AM, Batra JK, Goldenberg GJ. Direct correlation between DNA topoisomerase II activity and cytotoxicity in Adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res. 1989;49:58-62.
36. Wang JC. DNA topoisomerases. Annu Rev Biochem. 1985;54:665-697.
37. Yang L, Wold MS, Li JJ, et al. Roles of DNA topoisomerases in simian virus 40 DNA replication in vitro. Proc Natl Acad Sci U S A. 1987;84:950-954.
38. Kim RA, Wang JC. A subthreshold level of DNA topoisomerases leads to the excision of yeast rDNA as extrachromosomal rings. Cell. 1989;57:975-985.
39. Adachi Y, Luke M, Laemmli UK. Chromosome assembly in vitro: topoisomerase II is required for condensation. Cell. 1991;64:137-148.
40. Cheng H, Markley JL. NMR spectroscopic studies of paramagnetic proteins: iron-sulfur proteins. Annu Rev Biophys Biomol Struct. 1995;24:209-237.
41. Gerdes J, Schwab U, Lemke H, et al. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Inst J Cancer. 1983;31:13-20.
42. Gerdes J, Lemke H, Baisch H, et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710-1715.
43. Sasaki K, Murakami T, Kawasaki M, et al. The cell cycle associated change of the Ki-67 reactive nuclear antigen expression. J Cell Physiol. 1987;133:579-584.
44. Wersto RP, Herz F, Gallagher RE, et al. Cell cycle-dependent reactivity with the monoclonal antibody Ki-67 during myeloid cell differentiation. Exp Cell Res. 1988;179:79-88.
45. Schwarting R, Gerdes J, Niehus J, et al. Determination of the growth fraction in cell suspensions by flow cytometry using the monoclonal antibody Ki-67. J Immunol Methods. 1986;90:65-70.
46. Baisch H, Gerdes J. Simultaneous staining of exponentially growing versus plateau phase cells with the proliferation-associated antibody Ki-67 and propidium iodide: analysis by flow cytometry. Cell Tissue Kinet. 1987;20:387-391.
47. Walker RA, Camplejohn RS. Comparison of monoclonal antibody Ki-67 reactivity with grade and DNA flow cytometry of breast carcinomas. Br J Cancer. 1988;57:281-283.
48. Silvestrini R, Costa A, Veneroni S, et al. Comparative analysis of different approaches to investigate cell kinetics. Cell Tissue Kinet. 1988;21:123-131.
49. 3H]-thymidine labelling index and monoclonal antibody Ki-67 in non-Hodgkin's lymphomas. Hematol Oncol. 1988;6:21-28.
50. Kamel OW, Franklin WA, Ringus JC, et al. Thymidine labeling index and Ki-67 growth fraction in lesions of the breast. Am J Pathol. 1989;134:107-113.
51. Sasaki K, Matsumura K, Tsuji T, et al. Relationship between labeling indices of Ki-67 and BrdUrd in human malignant tumors. Cancer. 1988;62:989-993.
52. Schrape S, Jones DB, Wright DH. A comparison of three methods for the determination of the growth fraction in non-Hodgkin's lymphoma. Br J Cancer. 1987;55:283-286.
53. Shepherd NA, Richman PI, England J. Ki-67 derived proliferative activity in colorectal adenocarcinoma with prognostic correlations. J Pathol. 1988;155:213-219.
54. Verheijen R, Kuijpers HJ, van Driel R, et al. Ki-67 detects a nuclear matrix-associated proliferation-related antigen, II: localization in mitotic cells and association with chromosomes. J Cell Sci. 1989;92:531-540.